Biography:
Dongqin Xia, In June 2015, graduated from the School of Integrative Medicine (Chinese and Western Medicine) at Chongqing Medical University of China. In February 2017, she began her clinical and research career at Chongqing Cancer Hospital. In September 2025, she is also pursuing a Ph.D. at Chongqing Medical University, focusing on the pharmacological mechanisms of natural active compounds in anti-tumor therapy. Her research aims to develop novel drugs based on natural active compounds for cancer treatment. She has led three scientific research projects, published three high-impact papers, and holds two patents in the field of oncology.



Fisetin reverses formaldehyde-induced malignant transformation in head and neck epithelial cells by suppressing E2F1/AREG-mediated glycolytic reprogramming